Rising applications in Oncology
Nanomedicine is a promising mode of cancer treatment and has several applications in oncology. Cancer has a major impact on United States and across the world. As per WHO, cancer is found to be one of the major causes of mortality and morbidity worldwide, with approximately 14 million new cases in 2012 and 8.2 million were the cancer-related deaths. Therefore the demand for nanomedicine in the market was in order to curb such high incidence rate and is expected to boost market. Researchers have been working on improvisation of techniques, to deliver chemotherapeutic agents precisely at the Nano level in tumorous tissues. Nanoscale objects are used by themselves or as parts of larger devices containing multiple nanoscale objects and due their small size, nanoscale devices can readily interact with the biomolecules on both the surface and the inner cells and they have the potential to diagnose and treat cancer. Nanoparticles are majorly been used as nanocarriers, to deliver the cytotoxic drugs to the tumor cells and tissues. The increasing incidence of cancer and importance of nanomedicine in modern cancer treatment procedures, are expected to drive the nanomedicines demand during the forecast period.
Huge costs of the medical devices
Cost is the main factor that is often overlooked, which is specifically important in the face of ever increasing healthcare cost and unpredictable reimbursement environment. Nanomedicines are no different; there are several FDA approved nanoparticle-based products in the market, which can be compared with their non-nanoparticle based counterparts. Although these formulations may be more efficient and less toxic than their counterparts, their costs may also be significantly high. The average cost per dose of anticancer drug doxorubicin is about USD 62-162, compared to USD 5,594 for Doxil, which is a nanoparticle containing doxorubicin. Similarly, the average cost per dose of anticancer drug Abraxane, a paclitaxel nanoformulation, is USD 5,054. Therefore, owing to the inability of the industry to find a cost-effective method of scaling up the production, the cost of nanomedicine therapies is likely to remain high over the forecast period. This high cost of nanoparticle-assisted medicine, relative to its traditional counterparts, is hindering the growth of the market.
US Healthcare Nanotechnology Market
The US-based pharmaceutical companies believe that nanomedicines is the next big thing, as it has been opening up newer and has more accurate options for the target drug delivery, and resulting in very few side effects. The Swiss Group’s Kadcyla received the approval of the United States in February 2017. The product treats breast cancer with very less side-effects. In addition with the booming R&D, United States has also initiated several measures in the recent times, to advance and develop the nanotechnology applications in healthcare. Owing to the large geriatric population, increasing need for diagnostics, growing need of augmented cancer therapies, government initiatives, and increasing awareness of nanomedicines, the US healthcare nanotechnology sector will witness substantial growth during the forecast period.
The key players in the market are ABBOTT LABORATORIES, COMBIMATRIX CORPORATION, GE HEALTHCARE, SIGMA-TAU PHARMACEUTICALS Inc., JOHNSON & JOHNSON, MALLINCKRODT Plc, MERCK & COMPANY, Inc., NANOSPHERE, Inc., PFIZER, and CELGENE CORPORATION.
Reasons to Purchase this Report
- Current and future healthcare nanotechnology market outlook in the developed and emerging markets
- Analyzing various perspectives of the market with the help of Porter’s five forces analysis
- The segment that is expected to dominate the market
- Regions that are expected to witness fastest growth during the forecast period
- Identify the latest developments, market shares and strategies employed by the major market players.
- 3 months analyst support along with the Market Estimate sheet in excel.
1.1 MARKET DEFINITION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. KEY INFERENCES
5. MARKET OVERVIEW
5.1 CURRENT MARKET SCENARIO
5.2 PORTER'S FIVE FORCES ANALYSIS
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF CONSUMERS
5.2.3 THREATS OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTE PRODUCT AND SERVICES
5.2.5 COMPETITIVE RIVALRY WITHIN THE INDUSTRY
6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)
6.1 MARKET DRIVERS
6.1.1 INCREASING INCIDENCE OF CARDIOVASCULAR DISEASES
6.1.2 INCREASING RESEARCH FUNDING
6.1.3 RISING AWARENESS OF NANOMEDICINE APPLICATION
6.1.4 RISING GERIATRIC POPULATION
6.2 MARKET RESTRAINTS
6.2.1 HIGH COSTS OF NANOTECHNOLOGY-BASED MEDICAL DEVICES
6.2.2 TIME-CONSUMING PRODUCT APPROVAL
6.4 KEY CHALLENGES
7. Market Segmentation
7.1 SEGMENTATION-BY APPLICATIONS
7.1.1 DRUG DELIVERY
7.1.4 ACTIVE IMPLANTS
7.1.5 IN-VITRO DIAGNOSTIC
7.1.6 IN-VIVO IMAGING
7.2 BY DISEASE
7.2.1 NEUROLOGICAL DISEASES
7.2.2 CARDIOVASCUAR DISEASES
7.2.4 DISPOSABLE IVD DEVICES
7.3 SEGMENTATION-BY GEOGRAPHY
7.3.1 NORTH AMERICA
18.104.22.168 UNITED STATES
22.214.171.124 UNITED KINGDOM
126.96.36.199 REST OF EUROPE
188.8.131.52 AUSTRALIA & NEW ZEALAND
184.108.40.206 SOUTH KOREA
220.127.116.11 REST OF ASIA-PACIFIC
7.3.4 MIDDLE EAST & AFRICA
18.104.22.168 SOUTH AFRICA
22.214.171.124 REST OF THE MIDDLE EAST & AFRICA
7.3.5 SOUTH AMERICA
126.96.36.199 REST OF SOUTH AMERICA
8. COMPETITIVE LANDSCAPE
8.1 MERGERS & ACQUISITION ANALYSIS
8.2 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
8.3 NEW PRODUCTS LAUNCHES
9. KEY PLAYERS
9.1 ABBOTT LABORATORIES
9.2 COMBIMATRIX CORPORATION
9.3 GE HEALTHCARE
9.4 SIGMA-TAU PHARMACEUTICALS, INC.
9.5 JOHNSON & JOHNSON
9.6 MALLINCKRODT PLC
9.7 MERCK & COMPANY, INC.
9.8 NANOSPHERE, INC.
9.9 PFIZER, INC.
9.10 CELGENE CORPORATION
10. FUTURE OF THE MARKET